Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2023-05-09 AGM Information
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, JUNE 12, 2023
AGM Information Classification · 95% confidence The document is a Form of Proxy for use at the Annual General Meeting (AGM) of Alphamab Oncology, scheduled for June 12, 2023. It includes instructions for shareholders to appoint proxies to vote on resolutions at the AGM, including receiving the audited financial statements and reports for the year ended December 31, 2022. The document is not the actual AGM materials or presentations but a proxy voting form related to the AGM. It is not an Annual Report or financial report itself, nor is it a voting results announcement. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including proxy forms. The document length (7261 characters) supports it being a detailed proxy form rather than a brief announcement or certification.
2023-05-09 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a formal notice of the Annual General Meeting (AGM) for Alphamab Oncology, detailing the date, time, location, agenda items including resolutions to be passed, re-election of directors, and other procedural notes. It explicitly states it is a "NOTICE OF ANNUAL GENERAL MEETING" and includes typical AGM content such as shareholder voting instructions, proxy information, and resolutions to be considered. There is no financial data or detailed report content, only the announcement and agenda for the AGM. Therefore, this document fits the category of AGM Information (AGM-R).
2023-05-09 English
(1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES&#x3b; (2) PROPOSED RE-ELECTION OF RETIRING DIRECTORS&#x3b; (3) PROPOSED RE-APPOINTMENT OF AUDITOR&#x3b; (4) PROPO
AGM Information Classification · 100% confidence The document is a circular from Alphamab Oncology dated May 10, 2023, containing detailed information about the upcoming Annual General Meeting (AGM) scheduled for June 12, 2023. It includes proposals for granting general mandates to repurchase and issue shares, re-election of retiring directors, re-appointment of auditor, adoption of amended articles of association, and the notice of the AGM itself. The document is comprehensive, over 15,000 characters, and includes proxy forms and explanatory statements related to the AGM agenda. This type of document is typically classified as AGM Information (AGM-R) because it provides materials and notices for the Annual General Meeting rather than being a full annual report, earnings release, or other financial report. It is not a report publication announcement since it contains substantive meeting materials and proposals. Therefore, the correct classification is AGM Information (AGM-R).
2023-05-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on authorized and issued shares, share options, and confirmations related to share capital for Alphamab Oncology. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content includes detailed tables of share capital movements, share options, and confirmations by an executive director. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is regulatory in nature, reporting share capital and share issuance movements as required by the exchange rules. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes. The document length (8927 characters) and detailed data support it being a substantive report rather than a brief announcement or certification. Therefore, the classification is SHA with high confidence.
2023-05-05 English
2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information Classification · 100% confidence The document is titled '2022 Environmental, Social and Governance Report' and covers the period from January 1, 2022 to December 31, 2022. It references ESG governance, stakeholder communication, environmental management, social responsibility, and corporate governance. It explicitly states it is prepared in accordance with the ESG Reporting Guide of the Hong Kong Stock Exchange. The content includes detailed ESG performance indicators, company values, and sustainability initiatives. There is no indication that this is an annual financial report, audit report, or earnings release. The document is comprehensive and substantive, not a brief announcement or certification. Therefore, it fits the definition of an Environmental & Social Information report (ESG report).
2023-04-27 English
2022 Annual Report
Annual Report Classification · 100% confidence The document is titled '2022 Annual Report ALPHAMAB ONCOLOGY' and contains detailed sections typical of an annual report, including Company Profile, Chairman's Statement, Corporate Information, Board of Directors, Audit Committee, Remuneration Committee, Nomination Committee, Strategy Committee, Joint Company Secretaries, Authorized Representatives, Auditor information, Share Registrar details, and extensive financial and operational information. It includes financial highlights, management discussion and analysis, corporate governance report, directors' report, independent auditor's report, consolidated financial statements, and notes to the financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content and structure align with the definition of an Annual Report (10-K). Therefore, the correct classification is Annual Report (10-K) with high confidence. FY 2022
2023-04-27 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.